{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:13:06Z","timestamp":1783523586109,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","award":["CMOR11303"],"award-info":[{"award-number":["CMOR11303"]}],"id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSC 101-2314-B-002-132-MY3"],"award-info":[{"award-number":["NSC 101-2314-B-002-132-MY3"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10557-025-07698-x","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:09:54Z","timestamp":1745381394000},"page":"251-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of Angiotensin Receptor-Neprilysin Inhibitors Use and Better Cardiorenal Outcomes in Patients With Heart Failure and Acute Kidney Disease"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-7780","authenticated-orcid":false,"given":"Jui-Yi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Chih","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"5","key":"7698_CR1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1053\/j.ackd.2018.08.004","volume":"25","author":"C Ronco","year":"2018","unstructured":"Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis. 2018;25(5):382\u201390. https:\/\/doi.org\/10.1053\/j.ackd.2018.08.004.","journal-title":"Adv Chronic Kidney Dis."},{"issue":"2","key":"7698_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00041552-200403000-00004","volume":"13","author":"D Silverberg","year":"2004","unstructured":"Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004;13(2):163\u201370. https:\/\/doi.org\/10.1097\/00041552-200403000-00004.","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"4","key":"7698_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrneph.2017.2","volume":"13","author":"LS Chawla","year":"2017","unstructured":"Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241\u201357. https:\/\/doi.org\/10.1038\/nrneph.2017.2.","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"7698_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.kint.2021.06.028","volume":"100","author":"NH Lameire","year":"2021","unstructured":"Lameire NH, Levin A, Kellum JA, et al. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2021;100(3):516\u201326. https:\/\/doi.org\/10.1016\/j.kint.2021.06.028.","journal-title":"Kidney Int."},{"key":"7698_CR5","doi-asserted-by":"publisher","first-page":"101760","DOI":"10.1016\/j.eclinm.2022.101760","volume":"55","author":"CC Su","year":"2023","unstructured":"Su CC, Chen JY, Chen SY, et al. Outcomes associated with acute kidney disease: a systematic review and meta-analysis. EClinMed. 2023;55:101760. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101760.","journal-title":"EClinMed."},{"issue":"36","key":"7698_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J."},{"issue":"11","key":"7698_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med."},{"issue":"9","key":"7698_CR8","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/ejhf.2421","volume":"24","author":"FR Mc Causland","year":"2022","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022;24(9):1591\u20138. https:\/\/doi.org\/10.1002\/ejhf.2421.","journal-title":"Eur J Heart Fail."},{"issue":"31","key":"7698_CR9","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","volume":"44","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan M, Mentz RJ, Claggett BL, et al. Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur Heart J. 2023;44(31):2982\u201393. https:\/\/doi.org\/10.1093\/eurheartj\/ehad344.","journal-title":"Eur Heart J."},{"issue":"1","key":"7698_CR10","doi-asserted-by":"publisher","first-page":"e2350050","DOI":"10.1001\/jamanetworkopen.2023.50050","volume":"7","author":"H-C Pan","year":"2024","unstructured":"Pan H-C, Chen J-Y, Chen H-Y, et al. Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease. JAMA Netw Open. 2024;7(1):e2350050. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50050.","journal-title":"JAMA Netw Open."},{"issue":"6","key":"7698_CR11","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jmii.2023.09.005","volume":"56","author":"VC Wu","year":"2023","unstructured":"Wu VC, Chen JY, Lin YH, Wang CY, Lai CC. Assessing the cardiovascular events and clinical outcomes of COVID-19 on patients with primary aldosteronism. J Microbiol Immunol Infect. 2023;56(6):1158\u201368. https:\/\/doi.org\/10.1016\/j.jmii.2023.09.005.","journal-title":"J Microbiol Immunol Infect."},{"issue":"1","key":"7698_CR12","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","volume":"15","author":"HC Pan","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, et al. GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024;15(1):5912. https:\/\/doi.org\/10.1038\/s41467-024-50199-y.","journal-title":"Nat Commun."},{"issue":"1","key":"7698_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12933-024-02364-2","volume":"23","author":"HW Lai","year":"2024","unstructured":"Lai HW, See CY, Chen JY, Wu VC. Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol. 2024;23(1):277. https:\/\/doi.org\/10.1186\/s12933-024-02364-2.","journal-title":"Cardiovasc Diabetol."},{"issue":"8","key":"7698_CR14","doi-asserted-by":"publisher","first-page":"e2427258","DOI":"10.1001\/jamanetworkopen.2024.27258","volume":"7","author":"MH Chuang","year":"2024","unstructured":"Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open. 2024;7(8):e2427258. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.27258.","journal-title":"JAMA Netw Open."},{"issue":"1","key":"7698_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12933-024-02424-7","volume":"23","author":"CA Wang","year":"2024","unstructured":"Wang CA, Lin LC, Chen JY, Wang WJ, Wu VC. Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis. Cardiovasc Diabetol. 2024;23(1):327. https:\/\/doi.org\/10.1186\/s12933-024-02424-7.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"7698_CR16","doi-asserted-by":"publisher","first-page":"10043","DOI":"10.1038\/s41467-024-54171-8","volume":"15","author":"JY Sheu","year":"2024","unstructured":"Sheu JY, Chang LY, Chen JY, et al. The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients. Nat Commun. 2024;15(1):10043. https:\/\/doi.org\/10.1038\/s41467-024-54171-8.","journal-title":"Nat Commun."},{"key":"7698_CR17","doi-asserted-by":"publisher","unstructured":"Chang LY, Liao HW, Chen JY, Wu VC. Enhanced outcomes in type 2 diabetes patients with acute kidney disease through thiazolidinedione. J Clin Endocrinol Metab. 2024. https:\/\/doi.org\/10.1210\/clinem\/dgae796.","DOI":"10.1210\/clinem\/dgae796"},{"key":"7698_CR18","doi-asserted-by":"publisher","first-page":"616522","DOI":"10.3389\/fphar.2021.616522","volume":"12","author":"JC-L Guo","year":"2021","unstructured":"Guo JC-L, Pan H-C, Yeh B-Y, et al. Associations between using Chinese herbal medicine and long-term outcome among pre-dialysis diabetic nephropathy patients: a retrospective population-based cohort study. Front Pharmacol. 2021;12:616522.","journal-title":"Front Pharmacol."},{"issue":"4","key":"7698_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/m16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167(4):268\u201374. https:\/\/doi.org\/10.7326\/m16-2607.","journal-title":"Ann Intern Med."},{"key":"7698_CR20","doi-asserted-by":"publisher","first-page":"101232","DOI":"10.1016\/j.eclinm.2021.101232","volume":"44","author":"HC Pan","year":"2022","unstructured":"Pan HC, Huang TM, Sun CY, et al. Predialysis serum lactate levels could predict dialysis withdrawal in Type 1 cardiorenal syndrome patients. EClinMed. 2022;44:101232. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101232.","journal-title":"EClinMed."},{"issue":"4","key":"7698_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","volume":"74","author":"HY Chang","year":"2019","unstructured":"Chang HY, Feng AN, Fong MC, et al. Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372\u201380. https:\/\/doi.org\/10.1016\/j.jjcc.2019.03.010.","journal-title":"J Cardiol."},{"issue":"1","key":"7698_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.mayocp.2022.06.007","volume":"98","author":"HY Chang","year":"2023","unstructured":"Chang HY, Lin CC, Chao CJ, et al. Real-world experience of angiotensin receptor-neprilysin inhibition in reduced ejection fraction heart failure patients with advanced kidney disease. Mayo Clin Proc. 2023;98(1):88\u201399. https:\/\/doi.org\/10.1016\/j.mayocp.2022.06.007.","journal-title":"Mayo Clin Proc."},{"issue":"2","key":"7698_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","volume":"10","author":"J Tromp","year":"2022","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2022;10(2):73\u201384. https:\/\/doi.org\/10.1016\/j.jchf.2021.09.004.","journal-title":"JACC Heart Fail."},{"issue":"6","key":"7698_CR24","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","volume":"95","author":"AA House","year":"2019","unstructured":"House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(6):1304\u201317. https:\/\/doi.org\/10.1016\/j.kint.2019.02.022.","journal-title":"Kidney Int."},{"issue":"16","key":"7698_CR25","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/cir.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the american heart association. Circulation. 2019;139(16):e840\u201378. https:\/\/doi.org\/10.1161\/cir.0000000000000664.","journal-title":"Circulation."},{"issue":"10","key":"7698_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneph.2016.113","volume":"12","author":"JC Schefold","year":"2016","unstructured":"Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12(10):610\u201323. https:\/\/doi.org\/10.1038\/nrneph.2016.113.","journal-title":"Nat Rev Nephrol."},{"issue":"1","key":"7698_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1592\/phco.22.1.27.33502","volume":"22","author":"S Nathisuwan","year":"2002","unstructured":"Nathisuwan S, Talbert RL. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure. Pharmacotherapy. 2002;22(1):27\u201342. https:\/\/doi.org\/10.1592\/phco.22.1.27.33502.","journal-title":"Pharmacotherapy."},{"issue":"2","key":"7698_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jchf.2020.09.013","volume":"9","author":"SP Murphy","year":"2021","unstructured":"Murphy SP, Prescott MF, Camacho A, et al. Atrial natriuretic peptide and treatment with sacubitril\/valsartan in heart failure with reduced ejection fraction. JACC Heart Fail. 2021;9(2):127\u201336. https:\/\/doi.org\/10.1016\/j.jchf.2020.09.013.","journal-title":"JACC Heart Fail."},{"issue":"5","key":"7698_CR29","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ndt\/gfu269","volume":"30","author":"P Judge","year":"2015","unstructured":"Judge P, Haynes R, Landray MJ, Baigent C. Neprilysin inhibition in chronic kidney disease. Nephrol Dial Transplant. 2015;30(5):738\u201343. https:\/\/doi.org\/10.1093\/ndt\/gfu269.","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"7698_CR30","doi-asserted-by":"publisher","first-page":"e002744","DOI":"10.1161\/circheartfailure.115.002744","volume":"9","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril\/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail. 2016;9(3):e002744. https:\/\/doi.org\/10.1161\/circheartfailure.115.002744.","journal-title":"Circ Heart Fail."},{"issue":"4","key":"7698_CR31","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","volume":"22","author":"W Mullens","year":"2020","unstructured":"Mullens W, Damman K, Testani JM, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the heart failure association of the european society of cardiology. Eur J Heart Fail. 2020;22(4):584\u2013603. https:\/\/doi.org\/10.1002\/ejhf.1697.","journal-title":"Eur J Heart Fail."},{"issue":"6","key":"7698_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6(6):489\u201398. https:\/\/doi.org\/10.1016\/j.jchf.2018.02.004.","journal-title":"JACC Heart Fail."},{"issue":"4","key":"7698_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401\u201314. https:\/\/doi.org\/10.1177\/0091270009343932.","journal-title":"J Clin Pharmacol."},{"issue":"9502","key":"7698_CR34","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/s0140-6736(05)67760-4","volume":"366","author":"BB Granger","year":"2005","unstructured":"Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366(9502):2005\u201311. https:\/\/doi.org\/10.1016\/s0140-6736(05)67760-4.","journal-title":"Lancet."},{"issue":"19","key":"7698_CR35","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","volume":"54","author":"F Triposkiadis","year":"2009","unstructured":"Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2009.05.015.","journal-title":"J Am Coll Cardiol."},{"key":"7698_CR36","doi-asserted-by":"publisher","first-page":"760152","DOI":"10.3389\/fcvm.2021.760152","volume":"8","author":"K Fu","year":"2021","unstructured":"Fu K, Hu Y, Zhang H, et al. Insights of worsening renal function in type 1 cardiorenal syndrome: from the pathogenesis. Biomarkers to Treatment Front Cardiovasc Med. 2021;8:760152. https:\/\/doi.org\/10.3389\/fcvm.2021.760152.","journal-title":"Biomarkers to Treatment. Front Cardiovasc Med."},{"issue":"2","key":"7698_CR37","doi-asserted-by":"publisher","first-page":"F171","DOI":"10.1152\/ajprenal.1980.239.2.F171","volume":"239","author":"WJ Arendshorst","year":"1980","unstructured":"Arendshorst WJ, Gottschalk CW. Glomerular ultrafiltration dynamics: euvolemic and plasma volume-expanded rats. Am J Physiol. 1980;239(2):F171-86. https:\/\/doi.org\/10.1152\/ajprenal.1980.239.2.F171.","journal-title":"Am J Physiol."},{"issue":"2","key":"7698_CR38","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/ehf2.13257","volume":"8","author":"S Jung","year":"2021","unstructured":"Jung S, Bosch A, Kolwelter J, et al. Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2021;8(2):1562\u201370. https:\/\/doi.org\/10.1002\/ehf2.13257.","journal-title":"ESC Heart Fail."},{"key":"7698_CR39","doi-asserted-by":"publisher","unstructured":"Sutanto H, Dobrev D, Heijman J. Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias. Int J Mol Sci. 2021;22(16). https:\/\/doi.org\/10.3390\/ijms22168994.","DOI":"10.3390\/ijms22168994"},{"issue":"4","key":"7698_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ejhf.2471","volume":"24","author":"W Mullens","year":"2022","unstructured":"Mullens W, Martens P, Testani JM, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the heart failure association of the european society of cardiology. Eur J Heart Fail. 2022;24(4):603\u201319. https:\/\/doi.org\/10.1002\/ejhf.2471.","journal-title":"Eur J Heart Fail."},{"issue":"4","key":"7698_CR41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11897-020-00463-1","volume":"17","author":"G Tersalvi","year":"2020","unstructured":"Tersalvi G, Dauw J, Martens P, Mullens W. Impact of sacubitril-valsartan on markers of glomerular function. Curr Heart Fail Rep. 2020;17(4):145\u201352. https:\/\/doi.org\/10.1007\/s11897-020-00463-1.","journal-title":"Curr Heart Fail Rep."},{"issue":"3","key":"7698_CR42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1681\/asn.2013060610","volume":"25","author":"VC Wu","year":"2014","unstructured":"Wu VC, Wu CH, Huang TM, et al. Long-term risk of coronary events after AKI. J Am Soc Nephrol. 2014;25(3):595\u2013605. https:\/\/doi.org\/10.1681\/asn.2013060610.","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"7698_CR43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","volume":"36","author":"J McMurray","year":"2015","unstructured":"McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015;36(7):434\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehu455.","journal-title":"Eur Heart J."},{"issue":"1","key":"7698_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4330\/wjc.v6.i1.4","volume":"6","author":"O Arjamaa","year":"2014","unstructured":"Arjamaa O. Physiology of natriuretic peptides: the volume overload hypothesis revisited. World J Cardiol. 2014;6(1):4\u20137. https:\/\/doi.org\/10.4330\/wjc.v6.i1.4.","journal-title":"World J Cardiol."},{"issue":"10","key":"7698_CR45","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M, et al. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228\u201334. https:\/\/doi.org\/10.1002\/ejhf.580.","journal-title":"Eur J Heart Fail."},{"issue":"1","key":"7698_CR46","doi-asserted-by":"publisher","first-page":"e003529","DOI":"10.1161\/circheartfailure.116.003529","volume":"10","author":"H Burnett","year":"2017","unstructured":"Burnett H, Earley A, Voors AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail. 2017;10(1):e003529. https:\/\/doi.org\/10.1161\/circheartfailure.116.003529.","journal-title":"Circ Heart Fail."},{"key":"7698_CR47","doi-asserted-by":"publisher","first-page":"794707","DOI":"10.3389\/fcvm.2022.794707","volume":"9","author":"FC Hsiao","year":"2022","unstructured":"Hsiao FC, Lin CP, Yu CC, Tung YC, Chu PH. Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study. Front Cardiovasc Med. 2022;9:794707. https:\/\/doi.org\/10.3389\/fcvm.2022.794707.","journal-title":"Front Cardiovasc Med."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07698-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:58:38Z","timestamp":1770202718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07698-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7698"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07698-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"8 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TriNetX platform adheres to both the Health Insurance Portability & Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR). Furthermore, the utilization of TriNetX for the current study received formal approval from the Institutional Review Board of Chi-Mei Medical Center (Approval No: 11210-E01). Our study was conducted in strict accordance with the ethical principles delineated in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have provided their consent for the publication of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}